Clinical trials: Hyperphosphatemia Undergoing Hemodialysis
Hyperphosphatemia, End Stage Renal Disease
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
To evaluate the efficacy and safety of ferric citrate tablet in the control of serum phosphorus levels in patients with chronic kidney disease undergoing hemodialysis.
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT04456803
- Testing
- Ferric citrate tablet, Sevelamer carbonate tablet
- Where
- 20 sites in China
- Volunteers
- 239 people
- Sponsor
- Sinomune Pharmaceutical Co., Ltd
CKD 5D, Hemodialysis, Hyperphosphatemia Undergoing Hemodialysis
Real-World Efficacy and Safety of Tenapanor Plus Phosphate Binders in Hemodialysis Patients With Hyperphosphatemia
The efficacy and safety of tenapanor plus PBs in Chinese patients are still unclear. Therefore, we aim to conduct a real-world study to explore the effect of combining two drugs with different mechanisms on hyperphosphatemia…
- Trial name
- NCT07776119
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Hyperphosphatemia, End Stage Renal Disease
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
To evaluate the efficacy and safety of ferric citrate capsules for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT03984760
- Testing
- Ferric Citrate, Sevelamer Carbonate
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Panion & BF Biotech Inc.
Hyperphosphatemia
Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate
To assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (Lanthanum Carbonate) in patients with hyperphosphatemia undergoing hemodialysis in a randomized, double-blind, parallel group study in comparison…
- Trial name
- NCT01514851
- Testing
- Lanthanum carbonate (BAY77-1931), Calcium carbonate
- Where
- 31 sites in Japan
- Volunteers
- 259 people
- Sponsor
- Bayer
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Low-Phosphate Diet and Fibroblast Growth Factor-23 Level
The aims of the study are to evaluate the effect of low-phosphate diet on FGF23 level and to determine the optimal amount of dietary phosphate restriction in hemodialysis patients.
- Conditions
- Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia, Dietary Intervention, Elevated Fibroblast Growth Factor-23
- Trial name
- NCT03367338
- Testing
- Low-phosphate diet
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- Wan-Chuan Tsai
Hyperphosphatemia, Maintenance Hemodialysis
Tenapanor in Maintenance Hemodialysis Patients
The investigators hypothesize that Tenapanor can improve serum phosphorus control and regulate intestinal metabolism in maintenance hemodialysis patients without increasing the risk of severe gastrointestinal adverse events.
- Trial name
- NCT07882017
- Testing
- Tenapanor
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Huashan Hospital
Hyperphosphatemia
Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)
An oral highly potent P binder Velphoro is a mixture of polynuclear iron(III) oxyhydroxide, sucrose, and starches. It was well tolerated in the clinical development program.
- Trial name
- VERIFIE (NCT02687594)
- Testing
- sucroferric oxyhydroxide
- Where
- 7 sites in France, Germany and 5 more
- Volunteers
- 1,400 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
End-stage Renal Disease
Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients
The goal of this clinical trial is to learn if Niacin has an effect on lipoprotein (a) concentration and hyperphosphatemia, which represent strong risk factors for cardiovascular diseases, in End-stage renal disease (ESRD)…
- Trial name
- NCT06406140
- Testing
- Niacin tablets 500 mg
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Al-Azhar University
End Stage Renal Disease, Hyperphosphatemia
A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis
The purpose is to evaluate the tolerability, safety and efficacy of VS-505 when given with meal for 8 weeks to hemodialysis patients with hyperphosphatemia
- Trial name
- NCT02469467
- Testing
- VS-505
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- KDL Inc.
Hyperphosphatemia
BAY 77-1931 Long-term Extension From Phase II Study
A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis
- Trial name
- NCT00769496
- Testing
- BAY 77-1931
- Where
- 14 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Bayer
Hyperphosphatemia
The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis
Hyperphosphatemia is a common complication of end-stage renal disease and particularly affects haemodialysis patients. Elevated serum phosphorus contributes to the development of secondary hyperparathyroidism, Mineral bone…
- Trial name
- NCT03163576
- Testing
- Niacin, Phosphate Binder
- Volunteers
- 150 people
- Sponsor
- Assiut University
Chronic Kidney Disease, Hyperphosphatemia Undergoing Hemodialysis
Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan
The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal
- Trial name
- NCT02510274
- Testing
- ASP3325
- Where
- 5 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc